← Back
Data updated: Mar 10, 2026
PUMA BIOTECH
Oncology
PUMA BIOTECH is a pharmaceutical company focused on Oncology. Key products include NERLYNX.
2017
Since
1
Drugs
-
Trials
0
Approved (2yr)
Recent Activity
No recent activity
SEC Filings
Pro
Loading...
Therapeutic Focus
Score weights: Approved drugs ×3, Phase 3 ×2, Phase 2 ×1, Phase 1 ×0.5
Oncology 100%
1 drugs Phase 2: 4
Pipeline Strength Pro
Loading...
Active (1)
Discontinued (0)
Company Info
- First Approval
- 2017-07-17
- Latest
- 2021-06-28
- Applications
- 1